Shuttle Pharmaceuticals Holdings, Inc.

Company Overview

Business Model: Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company focused on developing novel therapies to cure cancers. The Company leverages proprietary technology to extend the benefits of existing cancer treatments, including surgery, radiation therapy, chemotherapy, and immunotherapy. Its product candidates aim to deliver safer, more reliable, and scalable cancer treatments than current standards of care. The corporate structure consists of Shuttle Pharmaceuticals Holdings, Inc. as the holding company, with drug discovery and development performed by its wholly-owned subsidiary Shuttle Pharmaceuticals, Inc., and diagnostics performed by its wholly-owned subsidiary Shuttle Diagnostics, Inc.

Market Position: The Company has established a leadership position in radiation sensitizer discovery and development, identifying two clinical-phase product candidates and new preclinical molecules over approximately seven years of research. It aims to address a critical need for new drugs that preferentially sensitize cancer cells to radiation therapy, stimulate innate immune responses, and provide imaging and molecular diagnostic tests for precision medicine in radiation oncology. The U.S. market for radiation sensitizing agents is experiencing dynamic growth, with over 50% of cancer patients undergoing radiotherapy and an estimated 22% increase in patients needing radiation therapy in the next 10 years.

Recent Strategic Developments:

• Ropidoxuridine Advancement: In December 2023, the Company submitted an Investigational New Drug (IND) application for Ropidoxuridine. In January 2024, it received a 'Safe to Proceed' letter from the U.S. Food and Drug Administration (FDA) for a Phase II study of Ropidoxuridine as a radiation sensitizing agent in patients with newly diagnosed IDH-wildtype glioblastoma with unmethylated MGMT promoter. The FDA also approved Orphan designation for Ropidoxuridine and radiation therapy for treating brain cancer (glioblastoma). The Phase II clinical study has commenced, with 17 patients enrolled as of February 24, 2025.
• HDAC Inhibitor Development: SP-2-225, a selective HDAC6 inhibitor, has been selected as a lead candidate for preclinical development, with studies initiated in collaboration with Georgetown University to explore immune activation after radiation therapy. Preclinical in vitro studies for SP-1-303, a selective Class I HDAC inhibitor, have been completed, and a manuscript is in preparation.
• Diagnostic Asset Development: Preclinical evaluations have been initiated for PSMA-B ligand as a potential prostate cancer sensitizer in combination with proton therapy, a PET diagnostic reagent, and a targeted prostate cancer therapeutic. Shuttle Diagnostics, Inc. was formed in November 2023 to advance these diagnostic assets.
• SBIR Contract Completions: The Company completed three Small Business Innovation Research (SBIR) contracts from the National Institutes of Health (NIH) for Ropidoxuridine clinical development, prostate cancer health disparities research, and predictive biomarker development for prostate cancer radiation late effects.
• Capital Raises: In October 2024, the Company completed an equity raise providing $4.0 million in net cash and an offering of senior secured convertible bridge notes providing $0.7 million in net cash.
• Nasdaq Compliance: On August 13, 2024, the Company effectuated a 1-for-8 reverse stock split to regain compliance with Nasdaq's minimum bid price requirement. However, as of December 31, 2024, the Company received a letter from Nasdaq indicating non-compliance with the minimum bid price requirement and, as of September 10, 2024, non-compliance with the minimum stockholders’ equity requirement. The Company has until June 30, 2025, to regain bid price compliance and until March 10, 2025, to regain stockholders' equity compliance.
• Leadership Appointment: Timothy J. Lorber assumed the full-time position of Chief Financial Officer on September 9, 2024.
• Cybersecurity Initiative: A Cybersecurity Subcommittee was established in January 2024 to identify, assess, and manage cybersecurity risks.

Geographic Footprint: The Company's corporate headquarters and all long-lived assets are located in Gaithersburg, Maryland, United States. Its intellectual property strategy focuses on obtaining worldwide patent coverage, particularly in significant global pharmaceutical markets.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: N/A
• Operating Margin: N/A
• Net Margin: N/A

Investment in Growth:

• R&D Expenditure: $3,618,796 (2024)
• Capital Expenditures: $0 (2024)
• Strategic Investments:
  • October 2024 Equity Offering: $4.0 million in net cash proceeds.
  • October 2024 Senior Secured Convertible Bridge Notes Offering: $0.7 million in net cash proceeds.

Business Segment Analysis

The Company operates as one operating segment, focusing on products designed to address limitations in current cancer therapies and extend applications of radiation therapy. The Chief Executive Officer, as the chief operating decision maker, manages and allocates resources on a consolidated basis, primarily considering research and development expenditures, cash burn, and net loss.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: The Company has not paid any dividends on its common stock since inception and does not expect to pay cash dividends in the foreseeable future, intending to retain all earnings for business development.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $1,920,144 (as of December 31, 2024)
• Total Debt: $874,475 (as of December 31, 2024)
• Net Cash Position: $1,045,669 (as of December 31, 2024)
• Credit Rating: Not disclosed.
• Debt Maturity Profile: The 2024 Convertible Bridge Notes mature in October 2025. A promissory note to an officer of the Company is repayable in equal monthly installments over one year, due September 2025.

Cash Flow Generation:

• Operating Cash Flow: $(7,327,230) (for the year ended December 31, 2024)
• Free Cash Flow: $(7,327,230) (for the year ended December 31, 2024)
• Cash Conversion Metrics: Not disclosed.

Operational Excellence

Production & Service Model: The Company does not own or operate manufacturing facilities. Good Manufacturing Practices (cGMP) synthesis of active pharmaceutical ingredients (API), drug formulation, and human dosage preparation are performed under contracts with third-party manufacturers. The Company relies on third-party supply and manufacturing partners for research and development, preclinical, and clinical trial drug supplies.

Supply Chain Architecture: Key Suppliers & Partners:

• Manufacturing: TCG GreenChem, Inc. (completed cGMP manufacture of Ropidoxuridine API in 2023). University of Iowa Pharmaceuticals (formulated Ropidoxuridine drug product for Phase II trials).
• Clinical Research: Theradex Oncology (now Theradex Systems, Inc.) - Contract Research Organization (CRO) engaged to assist in Phase II clinical trials. A change order in January 2025 increased the total cost limit for clinical trial support by $3.0 million, to an aggregate of $5.3 million.

Facility Network:

• Manufacturing: No owned facilities.
• Research & Development: Leases approximately 2,109 square feet of office and laboratory space at 401 Professional Drive, Suite 260, Gaithersburg, Maryland. The lease has an initial term of 5.25 years with an option to extend for an additional three years.
• Distribution: Not disclosed.

Operational Metrics: Not explicitly disclosed beyond R&D expenditure.

Market Access & Customer Relationships

Go-to-Market Strategy: The Company currently lacks internal marketing, sales, and distribution capabilities. If marketing and commercialization approval is received for any product candidates, the Company intends to market products either directly or through collaborations, strategic alliances, and distribution agreements with third parties.

Customer Portfolio: Not applicable as the Company is in the clinical stage with no commercial sales.

Geographic Revenue Distribution: Not applicable as the Company has no revenue.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The U.S. market for radiation sensitizing agents is experiencing dynamic growth driven by new radiation technology, new agents, an increasing number of diagnosed cancer patients, and evolving treatment patterns. Over 50% of all cancer patients undergo some form of radiotherapy, and the number of patients requiring radiation therapy is projected to increase by 22% in the next 10 years. The ideal radiation sensitizer would selectively act in tumors, have predictable pharmacokinetics, be administrable with various radiation treatments, and have minimal or manageable toxicity.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors: The Company faces competition from multinational pharmaceutical companies, specialized biotechnology companies, universities, and research institutions developing new technologies. Cetuximab (Erbitux, Eli Lilly/Imclone) is the only FDA-approved radiation sensitizer. Other drugs used off-label as radiation sensitizing agents include bevacizumab (Avastin, Roche), panitumumab (Vectibix, Amgen), and temozolomide (Temodar, Merck).

Emerging Competitive Threats: New entrants, disruptive technologies, and alternative solutions that offer greater effectiveness, increased quality, and better tolerability for patients pose competitive threats.

Competitive Response Strategy: The Company's strategy includes capitalizing on Ropidoxuridine as an orally available small molecule radiation sensitizer, expanding its leadership in radiation sensitizers to include proton therapy applications, executing a disciplined business development strategy through in-house discovery, partnerships, and in-licensing, investing in its HDAC platform technology for various cancer therapies and immune regulation, and seeking collaborations to maximize the platform's potential.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: The Company faces risks from the market's potential un-receptiveness to its novel therapeutic modality, as well as unfavorable and unstable global market and economic conditions, including those caused by geopolitical conflicts (Ukraine/Russia, Middle East) and the COVID-19 pandemic. Rising inflation rates and interest rates may increase operating costs and limit access to capital. Technology Disruption: Competitors may develop product candidates or technologies more rapidly or effectively, potentially rendering the Company's products obsolete or noncompetitive. Customer Concentration: Not applicable at the current stage of development.

Operational & Execution Risks

Supply Chain Vulnerabilities: The Company relies on third-party manufacturing and supply partners, which introduces risks of limited, interrupted, or unsatisfactory quality of research, development, and clinical trial materials. Geographic Concentration: All long-lived assets are held in the United States, potentially concentrating geographic risk. Capacity Constraints: Not explicitly mentioned as a current risk.

Financial & Regulatory Risks

Market & Financial Risks: The Company's ability to continue as a going concern is dependent on successfully raising additional equity or debt financing, as it has incurred significant losses and has insufficient funds for operations and clinical trials for the next 12 months. Its stock price may be volatile, and future equity or convertible debt issuances could dilute existing shareholders. Regulatory & Compliance Risks: The Company is subject to extensive U.S. and foreign governmental regulations for drug development, manufacturing, and commercialization. Failure to comply with these, including FDA requirements, cGMP, healthcare fraud and abuse laws (e.g., anti-kickback, false claims, HIPAA, HITECH Act, Open Payments), and pricing/reimbursement regulations, could lead to enforcement actions, withdrawal of approvals, and harm to its business. The Company is also non-compliant with Nasdaq's minimum bid price and stockholders' equity requirements, risking delisting. Legal Proceedings: There are no legal proceedings pending or threatened against the Company.

Geopolitical & External Risks

Geopolitical Exposure: Ongoing geopolitical conflicts (Ukraine/Russia, Middle East) could lead to market disruptions, volatility in commodity prices, credit and capital markets, and supply chain disruptions. Sanctions and other actions could adversely affect operations and access to funds. Trade Relations: Not explicitly detailed beyond general regulatory mention. Sanctions & Export Controls: Not explicitly detailed beyond general regulatory mention.

Innovation & Technology Leadership

Research & Development Focus: The Company's R&D efforts are focused on developing novel cancer therapies, including small molecule radiation sensitizers and immune response regulating drugs, to address limitations of current cancer treatments and expand applications of radiation therapy. Core Technology Areas:

• Radiation Sensitizers: Ropidoxuridine, an orally available halogenated pyrimidine, is a lead clinical-phase candidate designed to sensitize cancer cells to radiation.
• HDAC Inhibitors: A small molecule technology delivery platform producing HDAC inhibitors (SP-1-161, SP-2-225, SP-1-303) designed to target cancer cells, protect healthy tissue, and activate immune responses by regulating gene expression.
• Diagnostics: Preclinical prostate cancer-oriented diagnostics assets include the PC-RAD Test (a blood test to predict clinical response to radiation therapy) and the PSMA-B ligand (for potential use as a theranostic agent). Innovation Pipeline:
• Ropidoxuridine and Tipiracil (IPdR/TPI): A new combination formulation demonstrating extended bioavailability, slated for preclinical development as a radiation sensitizer.
• PSMA-B Ligand: Preclinical evaluations initiated for use as a prostate cancer sensitizer with proton therapy, a PET diagnostic reagent, and a targeted therapeutic.

Intellectual Property Portfolio: The Company holds 20 granted patents, including five core patents for its HDAC small molecule delivery platform and one for Ropidoxuridine. Its strategy is to obtain worldwide patent coverage and rely on trade secret protection for confidential know-how.

Technology Partnerships:

• Georgetown University: Collaborations include SBIR projects (African American prostate cancer health disparities, metabolomic predictive biomarker), an exclusive license for "Predictive Biomarkers for Adverse Effects of Radiation Therapy" patent rights, a research agreement for testing small molecule candidates, and a material transfer agreement.
• Brown University: Sub-contractor for the SBIR-supported Phase I clinical trial of Ropidoxuridine and radiation therapy.
• University of Virginia: Research collaboration to develop heavy oxygen molecules for proton radiation sensitizer applications.
• George Washington University: Material transfer agreement for testing HDAC inhibitor effects in immune model systems.
• Propagenix, Inc.: License agreement for "conditional re-programmed cell" (CRC) technology.
• Regents of the University of California (UCSF): Sponsored research agreement for "Investigation of 18F-fluorodeboronation method for PSMA targeting ligand radiolabeling and evaluation in prostate cancer models."

Leadership & Governance

Executive Leadership Team

Leadership Continuity: The Company's success is highly dependent on the continued service of its key management and specialized personnel. It faces competition for talent from other companies and research institutions.

Board Composition: The Board of Directors consists of six directors, four of whom are independent. The Board has an Audit Committee (Chair: Steve Richards, MBA, CPA), a Compensation Committee (Chair: Steve Richards), and a Nominating and Corporate Governance Committee (Chair: Joshua Schafer). At least one member of the Audit Committee qualifies as an "audit committee financial expert." The Nominating and Corporate Governance Committee considers diversity of background (race, ethnicity, international background, gender, and age) when evaluating director candidates.

Human Capital Strategy

Workforce Composition: As of the date of the Annual Report, the Company has nine full-time employees, including six executive officers and three employees engaged in research and development.

Talent Management: Acquisition & Retention: The Company's future success depends on its ability to attract and retain highly qualified scientific, technical, and management personnel, as well as those with expertise in clinical testing, manufacturing, governmental regulation, and commercialization.

Diversity & Development: The Company's founders, leadership team, and Board of Directors exemplify diversity and inclusivity with respect to race, sex, and ethnic origin.

Environmental & Social Impact

Environmental Commitments: The Company's research, development, and manufacturing activities involve hazardous materials and various chemicals. It is subject to federal, state, and local laws and regulations governing their use, manufacture, storage, handling, and disposal. The Company believes its procedures comply with relevant guidelines.

Supply Chain Sustainability: Not explicitly disclosed.

Social Impact Initiatives: The Company has engaged in prostate cancer health disparities studies, funded by SBIR contracts, to address the higher risk of prostate cancer and cancer-specific death rates in African American men compared to Caucasian American men. This includes developing African American prostate cancer cell lines.

Business Cyclicality & Seasonality

Demand Patterns: The growth in the number of cancer patients, driven by an aging population and improved diagnostic tools, contributes to the demand for cancer treatments. Over 80% of U.S. cancers occur in individuals aged 50 and above, with over 60% in those 65 and over.

Planning & Forecasting: Not explicitly disclosed.

Regulatory Environment & Compliance

Regulatory Framework: The Company's product candidates and activities are subject to extensive governmental regulations in the U.S. and foreign jurisdictions, covering research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising, promotion, pricing, marketing, and distribution of drugs.

Industry-Specific Regulations: Key regulations include those from the FDA (e.g., IND, cGMP, post-market authority, REMS), federal and state healthcare fraud and abuse laws (e.g., anti-kickback, false claims, HIPAA, HITECH Act, Open Payments), and healthcare reform initiatives such as the Patient Protection and Affordable Care Act (ACA) and the 340B Drug Pricing Program.

Trade & Export Controls: Not explicitly detailed.

Legal Proceedings: There are no legal proceedings pending or threatened against the Company.

Tax Strategy & Considerations

Tax Profile: The Company reported no income tax expense or benefit for the years ended December 31, 2024, and 2023, due to a full valuation allowance against its net operating loss (NOL) carryforwards. For tax reporting purposes, the Company capitalized $3,543,023 and $3,517,485 of R&D expenses incurred as of December 31, 2024, and 2023, respectively, as required by the Tax Cuts and Jobs Act of 2017 (TCJA). As of December 31, 2024, the Company had approximately $10.9 million in federal and $6.4 million in state NOL carryforwards. It also holds $200,715 in federal Research and Development (R&D) tax credits.

Insurance & Risk Transfer

Risk Management Framework: The Company's business involves significant product liability risks inherent in the development, testing, manufacturing, and marketing of therapeutic treatments. It maintains product liability insurance deemed appropriate for its current stage of development. However, the Company does not maintain insurance for environmental liability or toxic tort claims.